EU Research 2004 - IESE Blog Networkweb.iese.edu/mba/health/Master/Sessions/EU Research 2004.pdf• Biochemical engineering components of cell factories ... Biodiversity , Plants,

Prof. Magdalene Rosenmöller

SANIT 2004 - EU Research 1

University of Navarra

EU Research in Health

SANIT - Management in the Health Sector 2004

Prof. Magdalene RosenmöllerIESE Business School - Barcelona

2University of Navarra




• Fourth Framework Programme 1994 – 1998– Biomedicine and Health (BIOMED 2) – Biotechnology Programme (BIOTECH 2) – Esprit, the EU information technologies programme– Telematics Application Programme (for Health Care)– INCO - Cooperation with 3rd countries & international organisations

• Fifth Framework Programme 1998 – 2002– Life - Quality of Life & Management of Living Resources– IST - User Friendly Information Society – INCO 2 - International Co-operation– JRC - Joint Research Centre

• Sixth Framework Programme 2002 – 2006– Quality of Life & Management of Living Resources– Life Sciences, genomics and biotechnology for Health– Information society technologies– Nanotechnologies and Nanosciences, knowledge based multifunctional materials,

new production processes and devices

• 7th Framework Programme 2006 – 2010– Quality of Life & Management of Living Resources– Technology Platforms– Future of research - Building FP7

Overview EC Research Programmes


Fourth Framework Progamme

• Biomedecine and Health Programme (BIOMED) implemented under the Fourth Framework Programme (1994-1998) ECU 595.5 million

• BIOTECH 2– aimed to improve our basic biological knowledge of living

systems and to increase productivity in a sustainable fashion, with respect to applications in agriculture, industry, health, nutrition and the environment. It also considered the ethical and socio-economic implications of biotechnology.

– Cell Factory




Biotechnology Programme

(BIOTECH 2) 1994-1998Cell factories• Biological components of cell factories: Microbial & Animal • Biochemical engineering components of cell factories• Integrated cell factoriesGenome analysis• Sequencing• Function search• In silico comparative analysisPlant and animal biotechnology• Plant molecular and cellular biology• Animal physiopathology ; Genome mapping, etc Cell communication in neurosciences , Development , Regeneration , Degeneration, Management of

information • Cell to cell communication in the nervous systemImmunology and transdisease vaccinologyStructural biologyPrenormative research, biodiversity and social acceptance• in vitro alternatives to animal experiments, biosafety, Microbial ecology, Biofertilizers, Biopesticides, Vaccines ,

Plants, Fishbiotechnology for the environment, Biodiversity , Plants, Animals, Microorganisms, Social acceptance

Infrastructures• Information infrastructures , Information resources A European network of bioinformatics nodes• Horizontal information resources: literature, directories, databases• Genetic archives and stock centres

Horizontal activities• ELSA: ethical, legal and social aspects• Public perception• Socio-economic impacts





Fifth Framework ProgrammeQuality of Life & Management of Living Resources

1998 – 2002• Food, Nutrition and Health• Cell Factory

– Linking the Ability to discover to the Ability to Exploit• Environment and Health

– Air pollution; Asthma & allergies; Electromagnetic fields; Cancer; Noise; etc• Sustainable Agriculture, Fisheries and Forestry• The Ageing Population and their Disabilities

Area 7 Chronic and Degenerative Diseases, Cancer, Diabetes, Cardiovascular Disease and Rare Diseases

Area 8 Research into Genomes and Diseases of Genetic OriginArea 9 NeurosciencesArea 10 Public Health and Health Services ResearchArea 11 Research Relating to Persons with DisabilitiesArea 12 Biomedical Ethics and Bioethics


6th EU Research Framework Programme

Life Sciences, Genomicsand Biotechnology for Health




1. Integrating European Research 13.3 billion €1. Integrating European Research 13.3 billion €

Thematic priorities Health, food, environment,

nano-technology, ICT, aeronautics, society

11.3 billion €

Thematic priorities Health, food, environment,

nano-technology, ICT, aeronautics, society

11.3 billion €

Other activitespolicy support and

anticipating S&T needs, horizontal SME support,

JRC, int. co-operation, etc.2 billion €

Other activitespolicy support and

anticipating S&T needs, horizontal SME support,

JRC, int. co-operation, etc.2 billion €

2. Structuring ERA2.6 billion €

2. Structuring ERA2.6 billion €

3. Strengthening the foundations of ERA

0.3 billion €

3. Strengthening the foundations of ERA

0.3 billion €

What is FP 6 (2002-2006) about?


1.1 Advanced genomics and its application for health - 1100 million €

1.1.a Fundamental knowledge and basic tools for functional genomics in all organisms (550 million €)

1.1.b Applications of knowledge and technologies in the field of genomics and biotechnology for health (550 million €)

1.2.a Application oriented genomic approaches to medical knowledge and technologies (755 million €)

1.2.b Combating cancer*1.2.c Confronting the major communicable

diseases linked to poverty (400 million €**)* around 400 million € earmarked for Cancer within Combating

major diseases and Advanced Genomics** including 200 million € for EDCTP

1.2 Combating major diseases - 1155 million €

FP6 Priority 1 Life sciences, genomicsand biotechnology for health




Lines of FP6Advanced genomics and its application for health• fundamental knowledge and basic tools for functional genomics in all

organisms• application of knowledge and technologies in the field of genomics and

biotechnology for healthCombating major diseases• application-oriented genomic approaches to major diseases• combating cancer• confronting the major communicable diseases linked to povertyBudget: (indicative)

Thematic Priority Life Sciences, genomics and biotechnology for health: EUR 2.514 million– Advanced genomics and its applications for health:1209– Combating major diseases:1305


FP6 Priority 1 Life sciences, genomicsand biotechnology for health

Four calls for proposals (2002-2006) 2255 million €

• First call: closed 119 contract currently under negotiations, approximately 600 million € with around 8 % going to SMEs2700 participants including around 10 % SMEs80 % of the proposals includes SMEs

• Second call: open with deadline 13 November 2003approximately 400 million €, more details presented later today

• Third and fourth call: 2004 and 2005




SSP – Scientific Support to Policies

Research for policy support

Main objectives:

• The activities under this heading will underpin the formulation and implementation of Community policies; in particular the common agricultural policy (CAP), the common fisheries policies (CFP), environment, energy, transport, health, development aid, consumer protection etc.

• Research in this area will be mainly carried out by means of Specific Targeted Projects and Coordination Actions. In duly justified cases, limited use can be made of Integrated Projects (IPs) and Networks of Excellence (NoEs)


Different Project under FP6 SSP

• Health Policy– Ageing– Macro – AHEAD– Micro – HEALTH Basket– Patient Mobility– Quality in Europe

• SARS• Research into policy – the interface• Organ Donation

Communicable Diseases / Networks• Other clinical / Epidemiology, etc..





e4p Project

• SSP – Scientific Support to PoliciesEuropean Commission FP6 SP1

• The Future for Patients in Europe– Europe for Patients, e4p

• Duration: 3 years, Feb. 2004 – Jan 2007• Benefits and challenges of enhanced patient

mobility in Europe– how the benefits can be increased– how challenges can be addressed




Project Objective

to contribute scientific evidence that will enable policy makers at

EU, national & regional levelto take concerted and coordinated action

to allow Europe’s citizens / patients to benefit from enhanced mobility in Europe


Other Programmes related to Health

• INCO– International cooperation in Dev Countries

• Marie Curie - Human resources and mobility – European Fellowships – International Fellowships – Research Training Networks – Conferences and Training Courses – Excellence Actions

• DG Sanco - Public Health Programme– Information systems– Rapid Reaction to Health Threats– Health Determinants

• INFSO - eHealth• Education

– Leonardo da Vinci - Community Vocational Training Action Programme (2000-2006)




INCOHealth Research in International Cooperation

• Health Systems & Health System Research– Determinants of Health– Implications of specific Health issues– Impacts of interventions– Health sector reforms– Quality of Care and of services– Inputs in health systems (HHRR, drigs., etc.)– Research methods– Citizen perspective and user involvement– Health policy

• Issues – North – South, involvement,– Sustainability, capacity building– GRPP – Getting research into Policy and Practice– Health system research systems


INFSO – Information Society

• eHealth– europa.eu.int/information_society/eeurope/2005/all_about/ehealth/index_en.htm

– Health Cards– Integrated care records– Evidence based decisions– Health portals– Quality of Health Websites – Telemedicine

• Nanotechnology– www.cordis.lu/nanotechnology/




The Future of Research in an enlarged European Union


The European Research Area• In March 2000, the Lisbon European Council set the

goal of becoming by 2010 “the most competitive and dynamic knowledge-based economy in the world, capable of sustainable economic growth with more and better jobs and greater social cohesion”. The project of creating a European Research Area, as proposed by the Commission in its Communication "Towards a European Research Area" was endorsed as a central element of The Lisbon strategy to achieve this goal.




The European Research Area

Objective European Research Area initiative:• Creation of an "internal market" in research - area of free

movement of knowledge, researchers and technology, with the aim of increasing cooperation, stimulating competition and achieving a better allocation of resources;

• Restructuring of the European research fabric, in particular by improved coordination of national research activities and policies, which account for most of the research carried out andfinanced in Europe;

• Development of a European research policy which not only addresses the funding of research activities, but also takes account of all relevant aspects of other EU and national policies.


European Research Area3 Weaknesses:• insufficient funding• lack of an environment to stimulate research and exploit results• fragmented nature of activities and the dispersal of resourcesObjective - 3 related and complementary concepts:• the creation of an "internal market" - area of free movement of

knowledge, researchers and technology, with the aim of increasing cooperation, stimulating competition and achieving a better allocation of resources;

• a restructuring of the European research fabric, in particular by improved coordination of national research activities and policies, which account for most of the research carried out andfinanced in Europe;

• the development of a European research policy which not only addresses the funding of research activities, but also takes account of all relevant aspects of other EU and national policies.




Strategy• Lisbon Strategy – 2000 - 2010

– Strategic Vision for Life Sciences and biotechnology up to 2010

– The most competitive and dynamic knowledge-based economy in the world capable of sustainable growth with more and better jobs, … within a decade.

– 30 points• Leadership in a sensitive area• Advantages – High Technologies

– Create growth, new jobs, – Benefit a wide range of sectors– Broader goals – sustainable development


Scoreboard www.cordis.lu/indicators/home.html#carte

Human resources in RTD • Researchers (FTE) per 1000 workforce • New S&T PhDs per 1000 population aged 25-34 years

Public and private investment in RTD• Total R&D expenditure in % of GDP • Industry financed R&D as % of industrial output • Share of government budget allocated to R&D (GBAORD) • Share of SMEs in publicly funded R&D executed by the business sector (%) • Venture capital-investment per 1000 GDP

Scientific and technological productivity• Scientific publications per million population • Highly cited publications per million population • European patents per million population • US patents per million population

Impact of RTD on economic competitiveness and employment• Labour productivity (GDP per hour worked) in PPS • Labour productivity (GDP per hour worked) annual average growth % • Value added in high-tech industries as % of GDP • Employment in high-tech industries as % of total employment • Value added of knowledge intensive services as % of GDP • Employment in knowledge intensive services as % of total employment • Technology balance of payments receipts as % of GDP • Technology balance of payments (exports-imports) as % of GDP • Exports of high-tech products as % of world total




Strategy 6th FP 2003 - 2006• Budget 17,5 billion Euros

• 5% of total public research spending in Europe

• Critical expertise, structural impact on research landscape in Europe

• + Participation SME, international scientific cooperation, research infrastructures, mobility & training of researchers

• Addresses issues such as

– Insufficient mobility, ‘brain-drain’, fragmentation & duplication of efforts, no transformation of research results into products and services

• More research for Europe Towards 3% of GDP

– EU, 1,9%, US 2.,7%, Japan 3%

– EU funds to be matched by national funds

– Cross border: nationals, and public / private

• World wide ban on human reproductive cloning


Strategic Vision7th Framework Programme

Strategic Vision of the future 7th Framework Programme

europa.eu.int/comm/research/future/themes/index_en.html

• Biotechnology -europa.eu.int/comm/biotechnology/introduction_en.html

• Technological Platformswww.cordis.lu/technology-platforms/home.htmlPlants for the Future www.epsoweb.org/Catalog/TP/index.htmInnovative Medicines

www.cordis.lu/lifescihealth/innovativemedicines.htm




Why more industry in EC funded research?

Important political targets for the EU• We should become the most competitive knowledge

based economy by 2010 - biotechnology identified as major growth area together with information technologies

• The overall spending on R&D and innovation should reach 3 % of GDP by 2010 (2/3 of the contribution should come from the private sector)

• Research intensive life science/biotech SMEs play an important role in reaching the above goals and thereby contributing to growth, innovation and employment


What could be the benefits of industry participation in EC funded projects ?

• Valuable results are lost today that should be translatedto application and should be exploited whenever possible

• Early access to newly generated knowledge can increase the competitive edge for European industry/SMEs

• Good opportunities for training and expansion of recruitment base and for dissemination of new results, methods and technologies

• Better mutual understanding of the academic and industrial cultures can bring mutual benefits (e.g. timing of market entry for gene therapy)

• Involve European industry/SMEs more in research activities to stimulate the total investment in research and innovation




What is the role of the EC in promoting and funding research?Funding agency

• Mainly supporting research done by multinational, multidisciplinary consortia in pre-defined areas through multi-annual framework programmes

• Framework Programme 6 (FP6), 2002-2006, has the objective to: strengthen the scientific and technological basis to increase the competitiveness of industry and encourage its international competitiveness while promoting research activities in support of other EU policies

Policy maker• European Research Area, 3% of GDP spent on R&D,

Life sciences and biotechnology strategy, etc.


What do the EC have on offer as a funding agency?

• 2.255 million € dedicated to Life sciences, genomics and biotechnology for health research (Priority 1)

• Additional opportunities for life science/biotech SMEs in other Priorities such as nanotechnolgies, food, etc.

• Industrial participation in research can be funded between 35-100 % depending on nature of work and type of project

• Special focus on SMEs with 15 % of the total budget earmarked for their participation

> 85 million € per year for SMEs in Priority 1




Stakeholders of EU Research

• European Institutions– European Parliament, European Economic and

Social Committee, Committee of the Regions• Member States – Governments

- eg. France www.cordis.lu/france/fr/home.html

• Regions, eg. – NRW - www.cordis.lu/nordrhein-westfalen/home.html– CAT - www.cordis.lu/catalonia/home.html

• Universities and Research institutions• Private sector – Pharma & BioTech

Companies• Commission’s Joint Research Centre (JRC)


Hindering Factors• Long term success of biotechnology in the Union?

– EU Biotech Industry = late starter – in early stage (company size, revenues, product pipelines)

• Biotechnology– Global, highly capital intensive and knowledge based industry– Problems: fragmentation, access to finance and intellectual property protection

• Member States– Transpose legislation

• Biotechnology patents, authorisation of GMOs, etc. • Intellectual property protection

– More funds needed• Interface public research systems – industry

– Insufficiently developed– EU firms turn to US for collaboration not to other EU companies– EU lags behind US in terms of patents and collaborative R&D projects, US = dominant

lead in innovative activities• Lack of international governance• EU-US BioTechnology Consultative Forum




Technology Platforms

• Technological Platforms– a unique feature of the European Commission's

biotechnology R&D programme – Objective - to improve links between fundamental

research and commercial applications in Europe and to help translate and accelerate new ideas into new products.

– participation from industry in the Biotechnology programme has increased significantly and the number of platforms has risen to 14


Example TP

• The European NANOMEDICINE Technology Platform Nanobiotechnologies for Medical Applications *

• The European Plant Genomics and Biotechnology Technology Platform **




Industrial Platforms• HAE 2000 - Healthy Ageing Europe Industrial Platform

• ACTIP - Animal Cell Technology Industrial Platform

• LABIP - Lactic Acid Bacteria Industrial Platform

• YIP - Yeast Industry Platform

• PIP - Plant Industry Platform

• IVTIP - In Vitro Testing Industrial Platform

• BACIP - Bacillus Subtilis Genome Industrial Platform

• FAIP - Farm Animal Industrial Platform

• IPM - Industry Platform for Microbiology

• SBIP - Structural Biology Industrial Platform

• BBP - Biotechnology for Biodiversity Platform

• FIP - Fungal Industry Platform

• E.NIP - European Neuroscience Industrial Platform

• EBIP - Environmental Biotechnology Industrial Platform

• TSE IP - TSE Industrial Platform

University of Navarra

Thank you for your attention!

[email protected]

http://www.iese.edu

Documents

EU Research 2004 - IESE Blog Networkweb.iese.edu/mba/health/Master/Sessions/EU Research 2004.pdf• Biochemical engineering components of cell factories ... Biodiversity , Plants,